Haemonetics Corporation (HAE) Fair Value 2026

HAE · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.8 /10

32 fundamental signals · 13 models active

Value Trap Risk

SAFE (23/100)

Quick Summary — As of 2026-07-13, Haemonetics Corporation (HAE) trades at $76.86, approximately 7% above CirclFi’s Bayesian DCF fair value of $71.92. QOC: 9.8/10. Value Trap Risk: 23/100 (SAFE). 13/13 models active.

Key Facts

Ticker
HAE
Price
$76.86
Quality Score
9.8/10
Value Trap Risk
23/100
Models Active
13/13
Last Updated
Strength: First Chicago suggests +36.4% upside with 60% confidence
Risk: Majority of models suggest overvaluation

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($76.86)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $71.92 -6.4%
Earnings Power Value
High Conviction
 $27.72 -63.9%
CUCE Ensemble
Low Conviction
 $60.17 -21.7%
First Chicago
High Conviction
 $104.82 +36.4%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is Haemonetics Corporation (HAE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Haemonetics Corporation's intrinsic value is estimated at a composite fair value of $64.19. Trading at $76.86, the stock is approaching fair value or slight overvaluation (implied return of -16.5%), as 8 of 13 models suggest limited further upside. Model dispersion is worth noting: Markov DDM targets $144.35 (+87.8%), versus Dynamic NAV at $4.33 (-94.4%). This +182.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About HAE?

13 of 13 models are currently active for HAE. Of these, 5 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates HAE's intrinsic value at $71.92, implying -6.4% downside from the current price. See which stocks rank higher →

How Does HAE Rank in Surgical & Medical Instruments & Apparatus?

Among 111 Surgical & Medical Instruments & Apparatus stocks, HAE ranks #6 by Quality of Company score. CirclFi's QOC score of 9.8/10 evaluates 32 fundamental signals. A score of 9.8 places HAE in the top tier.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

Haemonetics Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HAE a Value Trap?

CirclFi's Value Trap algorithm assigns HAE a score of 23/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for Haemonetics Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Haemonetics Corporation earns a quality score of 9.8/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +182.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HAE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HAE's 13 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Haemonetics Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

DXCMDexCom, Inc.QOC 10.0IRMDiRadimed CorporationQOC 10.0PODDInsulet CorporationQOC 10.0RMDResMed Inc.QOC 10.0WSTWest Pharmaceutical Services, IQOC 9.9LMATLeMaitre Vascular, Inc.QOC 9.8GMEDGlobus Medical, Inc.QOC 9.2TCMDTactile Systems Technology, IncQOC 9.0

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About Haemonetics Corporation

What is Haemonetics Corporation's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Haemonetics Corporation (HAE) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $71.92. The Quality of Company score is 9.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HAE overvalued or undervalued right now?

At $76.86, 5 of 13 active models suggest HAE may be undervalued, while 8 indicate potential overvaluation. The assessment depends on which methodology best fits Haemonetics Corporation's business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 9.8 mean for HAE?

Haemonetics Corporation's QOC of 9.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on HAE?

CirclFi analyzes HAE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is HAE a value trap in 2026?

Haemonetics Corporation's Value Trap score is 23/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on HAE.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access